Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
July 01, 2021 06:00 ET
|
Arcutis Biotherapeutics, Inc.
Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligoCompany progressing new formulation with goal of greater drug...
Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
June 23, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
June 09, 2021 16:01 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer
June 01, 2021 07:30 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 11, 2020 16:05 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...